BDTX Stock Summary and Trading Ideas (Black Diamond Therapeutics | NASDAQ:BDTX)

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Black Diamond Therapeutics trades on the NASDAQ stock market under the symbol BDTX.

As of February 20, 2026, BDTX stock price climbed to $2.33 with 470,593 million shares trading.

BDTX has a beta of 1.72, meaning it tends to be more sensitive to market movements. BDTX has a correlation of 0.18 to the broad based SPY ETF.

BDTX has a market cap of $132.66 million. This is considered a Micro Cap stock.

In the last 3 years, BDTX traded as high as $7.66 and as low as $1.20.

The top ETF exchange traded funds that BDTX belongs to (by Net Assets): VTI, VXF, FESM, IBB, BSVO.

BDTX has underperformed the market in the last year with a return of -1.7%, while the SPY ETF gained +13.7%. In the last 3 month period, BDTX fell short of the market, returning -40.1%, while SPY returned +4.3%. However, in the most recent 2 weeks BDTX has outperformed the stock market by returning +7.9%, while SPY returned +1.7%.

BDTX support price is $2.21 and resistance is $2.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDTX shares will trade within this expected range on the day.